نبذة مختصرة : This study starts from the metabolic related indexes and cellular inflammatory factors in patients with chronic schizophrenia to find out that it can be used as an effective screening index of metabolic syndrome. 320 patients with chronic schizophrenia (course of disease > 5 years) and 165 healthy subjects were selected. The mental symptoms of the patients were measured by positive and negative syndrome scale. Blood samples from patients and healthy controls were collected to detect blood glucose, triglyceride, HDL and fasting insulin. The serum levels of IL-1β, IL-2, IL-6, IL-17, IFN-γ and TNF-α were determined repeatedly by sandwich enzyme-linked immunosorbent assay. The levels of HOMA-IR, plasma inflammatory factors IL-2, IL-6, IL-17 and TNF-α in patient group were higher than those in healthy group. It was found that there were differences in age and related metabolic indexes between patients with chronic schizophrenia with and without metabolic syndrome. In addition, HOMA-IR, plasma cytokines IL-2 and IL-6 still showed differences between groups. In the Spearmen correlation analysis of insulin resistance index, cytokines and metabolic indexes, it was found that there was a significant correlation between HOMA-IR, IL-6 and related metabolic indexes and metabolic syndrome. ROC curve analysis showed that HOMAIR and IL-6 could be used as screening indexes for MS in male and female patients with schizophrenia.Metabolic syndrome is an important risk factor for cardiovascular disease in patients with chronic schizophrenia. HOMA-IR and IL-6 can be used as effective biological indicators to screen MS in patients with chronic schizophrenia.
(© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.)
References: Huang Y, Wang YU, Wang H et al (2019) Prevalence of mental disorders in China: a cross-sectional epidemiological study. Lancet Psychiatry 6(3):211–224. https://doi.org/10.1016/S2215-0366(18)30511-X. (PMID: 10.1016/S2215-0366(18)30511-X30792114)
Kritharides L, Rye KA, Lambert TJ et al (2016) Lipidology, cardiovascular risk, and schizophrenia. Curr Opin Lipidol 27(3):305–307. https://doi.org/10.1097/MOL.0000000000000307. (PMID: 10.1097/MOL.000000000000030727145103)
Katsiki N, Athyros VG, Karagiannis A et al (2014) Metabolic syndrome and non-cardiac vascular diseases: an update from human studies. Curr Pharm Des 20(31):4944–4952. https://doi.org/10.2174/1381612819666131206100750. (PMID: 10.2174/138161281966613120610075024320038)
Grundy SM, Cleeman JI, Daniels SR (2005) Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation 112(17):2735–2752. https://doi.org/10.1161/CIRCULATIONAHA.105.169404. (PMID: 10.1161/CIRCULATIONAHA.105.16940416157765)
Hu G, Qiao Q, Tuomilehto J et al (2004) Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med 164(10):1066–1076. https://doi.org/10.1001/archinte.164.10.1066. (PMID: 10.1001/archinte.164.10.106615159263)
Girman CJ, Rhodes T, Mercuri M et al (2004) The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas coronary atherosclerosis prevention study (AFCAPS/TexCAPS). Am J Cardiol 93(2):136–141. https://doi.org/10.1016/j.amjcard.2003.09.028. (PMID: 10.1016/j.amjcard.2003.09.02814715336)
Lakka HM, Laaksonen DE, Lakka TA et al (2002) The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288(21):2709–2716. https://doi.org/10.1001/jama.288.21.2709. (PMID: 10.1001/jama.288.21.270912460094)
Malik S, Wong ND, Franklin SS et al (2004) Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 110(10):1245–1250. https://doi.org/10.1161/01.CIR.0000140677.20606.0E. (PMID: 10.1161/01.CIR.0000140677.20606.0E15326067)
Rochlani Y, Pothineni NV, Kovelamudi S et al (2017) Metabolic syndrome: pathophysiology, management, and modulation by natural compounds. Ther Adv Cardiovasc Dis 11(8):215–225. https://doi.org/10.1177/1753944717711379. (PMID: 10.1177/1753944717711379286395385933580)
Mohamed-Ali V, Pinkney JH, Coppack SW (1998) Adipose tissue as an endocrine and paracrine organ. Int J Obes Relat Metab Disord 22(12):1145–1158. https://doi.org/10.1038/sj.ijo.0800770. (PMID: 10.1038/sj.ijo.08007709877249)
Spangenburg EE (2007) Interleukin-6 does/does not have a beneficial role in insulin sensitivity and glucose homeostasis. J Appl Physiol 102(2):820–823. https://doi.org/10.1152/japplphysiol.01353.2006. (PMID: 10.1152/japplphysiol.01353.200617284658)
Haidara M, Mikhailidis DP, Yassin HZ et al (2011) Evaluation of the possible contribution of antioxidants administration in metabolic syndrome. Curr Pharm Des 17(33):3699–3712. https://doi.org/10.2174/138161211798220882. (PMID: 10.2174/13816121179822088222074439)
Trayhurn P, Wood IS (2004) Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 92(3):347–355. https://doi.org/10.1079/bjn20041213. (PMID: 10.1079/bjn2004121315469638)
Jacobs M, Van Greevenbroek MMJ, Van Der Kallen CJH et al (2009) Low-grade inflammation can partly explain the association between the metabolic syndrome and either coronary artery disease or severity of peripheral arterial disease: the CODAM study. Eur J Clin Invest 39(6):437–444. https://doi.org/10.1111/j.1365-2362.2009.02129.x. (PMID: 10.1111/j.1365-2362.2009.02129.x19397692)
Kirilmaz B, Asgun F, Alioglu E et al (2010) High inflammatory activity related to the number of metabolic syndrome components. J Clin Hypertens 12(2):136–144. https://doi.org/10.1111/j.1751-7176.2009.00229.x. (PMID: 10.1111/j.1751-7176.2009.00229.x)
Gonçalves FM, Jacob-Ferreira ALB, Gomes VA et al (2009) Increased circulating levels of matrix metalloproteinase (MMP)-8, MMP-9, and pro-inflammatory markers in patients with metabolic syndrome. Clin Chim Acta 403(1–2):173–177. https://doi.org/10.1016/j.cca.2009.02.013. (PMID: 10.1016/j.cca.2009.02.01319254704)
Ter Horst R, van den Munckhof ICL, Schraa K et al (2020) Sex-specific regulation of inflammation and metabolic syndrome in obesity. Arterioscler Thromb Vasc Biol 40(7):1787–1800. https://doi.org/10.1161/ATVBAHA.120.314508. (PMID: 10.1161/ATVBAHA.120.314508324605797310302)
Yuan X, Wang S, Shi Y et al (2022) Pro-inflammatory cytokine levels are elevated in female patients with schizophrenia treated with clozapine. Psychopharmacology 239(3):765–771. https://doi.org/10.1007/s00213-022-06067-y. (PMID: 10.1007/s00213-022-06067-y35080634)
Leucht S, Samara M, Heres S et al (2016) Dose equivalents for antipsychotic drugs: the DDD method. Schizophr Bull 42(Suppl 1):S90-94. https://doi.org/10.1093/schbul/sbv167. (PMID: 10.1093/schbul/sbv167274606224960429)
Liu Z, Zhang Y, Zhao T et al (2020) A higher body mass index in Chinese inpatients with chronic schizophrenia is associated with elevated plasma orexin-A levels and fewer negative symptoms. Nord J Psychiatry 74(7):525–532. https://doi.org/10.1080/08039488.2020.1755995. (PMID: 10.1080/08039488.2020.175599532363986)
Hanley AJG, Williams K, Stern MP et al (2002) Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease: the San Antonio Heart Study. Diabetes Care 25(7):1177–1184. https://doi.org/10.2337/diacare.25.7.1177. (PMID: 10.2337/diacare.25.7.117712087016)
Chen BD, Yang DG, Chen YU et al (2010) The prevalence of microalbuminuria and its relationships with the components of metabolic syndrome in the general population of China. Clin Chim Acta 411(9–10):705–709. https://doi.org/10.1016/j.cca.2010.01.038. (PMID: 10.1016/j.cca.2010.01.03820138167)
Wu X, Xia L, Yang Y et al (2022) Mortality among psychiatric inpatients in China: a national survey. Asian J Psychiatr 77:103262. https://doi.org/10.1016/j.ajp.2022.103262. (PMID: 10.1016/j.ajp.2022.10326236181753)
Grundy SM (2008) Metabolic syndrome pandemic. Arterioscler Thromb Vasc Biol 28(4):629–636. https://doi.org/10.1161/ATVBAHA.107.151092. (PMID: 10.1161/ATVBAHA.107.15109218174459)
Silveira Rossi JL, Barbalho SM, Reverete de Araujo R et al (2022) Metabolic syndrome and cardiovascular diseases: going beyond traditional risk factors. Diabetes Metab Res Rev 38(3):e3502. https://doi.org/10.1002/dmrr.3502. (PMID: 10.1002/dmrr.350234614543)
Monda V, Salerno M, Sessa F et al (2018) Functional changes of orexinergic reaction to psychoactive substances. Mol Neurobiol 55(8):6362–6368. https://doi.org/10.1007/s12035-017-0865-z. (PMID: 10.1007/s12035-017-0865-z29307079)
Velázquez-López L, Santiago-Díaz G, Nava-Hernández J et al (2014) Mediterranean-style diet reduces metabolic syndrome components in obese children and adolescents with obesity. BMC Pediatr 14:175. https://doi.org/10.1186/1471-2431-14-175. (PMID: 10.1186/1471-2431-14-175249976344102089)
Sayón-Orea C, Razquin C, Bulló M et al (2019) Effect of a nutritional and behavioral intervention on energy-reduced Mediterranean diet adherence among patients with metabolic syndrome: interim analysis of the PREDIMED-Plus randomized clinical trial. JAMA 322(15):1486–1499. https://doi.org/10.1001/jama.2019.14630. (PMID: 10.1001/jama.2019.14630316133466802271)
Guo Y, Luo S, Ye Y et al (2021) Intermittent fasting improves cardiometabolic risk factors and alters gut microbiota in metabolic syndrome patients. J Clin Endocrinol Metab 106(1):64–79. https://doi.org/10.1210/clinem/dgaa644. (PMID: 10.1210/clinem/dgaa64433017844)
Xiao J, Wu CL, Gao YX et al (2016) Prevalence of metabolic syndrome and its risk factors among rural adults in Nantong, China. Sci Rep 6:38089. https://doi.org/10.1038/srep38089. (PMID: 10.1038/srep38089279010765128865)
Wang S, Shi J, Peng Y et al (2016) Stronger association of triglyceride glucose index than the HOMA-IR with arterial stiffness in patients with type 2 diabetes: a real-world single-centre study. Cardiovasc Diabetol 20(1):82. https://doi.org/10.1186/s12933-021-01274-x. (PMID: 10.1186/s12933-021-01274-x)
Dogra M, Jaggi S, Aggarwal D et al (2022) Role of interluekin-6 and insulin resistance as screening markers for metabolic syndrome in patients of chronic obstructive pulmonary disease. A hospital based cross-sectional study. Monaldi Arch Chest Dis. https://doi.org/10.4081/monaldi.2021.2024. (PMID: 10.4081/monaldi.2021.2024)
Cases JA, Barzilai N (2000) The regulation of body fat distribution and the modulation of insulin action. Int J Obes Relat Metab Disord 24(Suppl 4):S63-66. https://doi.org/10.1038/sj.ijo.0801508. (PMID: 10.1038/sj.ijo.080150811126245)
Pickup JC, Chusney GD, Thomas SM et al (2000) Plasma interleukin-6, tumour necrosis factor α and blood cytokine production in type 2 diabetes. Life Sci 67(3):291–300. https://doi.org/10.1016/s0024-3205(00)00622-6. (PMID: 10.1016/s0024-3205(00)00622-610983873)
Tiwari S, Gupta V, Paul BN et al (2015) IL-6 gene expression in adipose tissue of postmenopausal women and its association with metabolic risk factors. Mol Cell Endocrinol 399:87–94. https://doi.org/10.1016/j.mce.2014.08.008. (PMID: 10.1016/j.mce.2014.08.00825301326)
Bastard JP, Maachi M, Van Nhieu JT et al (2002) Adipose tissue IL-6 content correlates with resistance to insulin activation of glucose uptake both in vivo and in vitro. J Clin Endocrinol Metab 87(5):2084–2089. https://doi.org/10.1210/jcem.87.5.8450. (PMID: 10.1210/jcem.87.5.845011994345)
Processing Request
No Comments.